J. Vasselli

发表

Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors

M. Wood, W. Linehan, J. Maranchie, 2004, Journal of cellular biochemistry.

Genetic Basis of Cancer of the Kidney

W. Marston Linehan, Peter Choyke, Maria Merino, 2004, Clinical Cancer Research.

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

N. Segal, M. Maio, S. Antonia, 2014 .

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

N. Segal, S. Antonia, J. Lutzky, 2014 .

1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA.

N. Segal, O. Hamid, M. Butler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

R. Herbst, J. Heymach, F. D. De Braud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

L. Paz-Ares, R. Haddad, B. Robinson, 2010, The Journal of clinical endocrinology and metabolism.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

R. Herbst, P. Elvin, A. Platt, 2015, BMC Cancer.

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

N. Rizvi, S. Antonia, J. Brahmer, 2014 .

A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.

A. Tolcher, P. Moore, N. Rizvi, 2016 .

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

K. Flaherty, A. Ribas, P. Moore, 2015, Journal of Immunotherapy for Cancer.

Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

L. Roskos, R. Narwal, P. Robbins, 2014 .

Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.

W. Linehan, J. Mcmahon, G. Woldemichael, 2012, Neoplasia.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

E. Baudin, A. Ryan, M. Santoro, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to J.-F. Chatal et al

E. Baudin, A. Ryan, M. Santoro, 2012 .

Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor

Joanna H Shih, Richard Simon, Richard D Klausner, 2003, Proceedings of the National Academy of Sciences of the United States of America.

VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

Richard D Klausner, Robert Stearman, W Marston Linehan, 2002, Cancer research.

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Richard D Klausner, W Marston Linehan, J. Bonifacino, 2002, Cancer cell.

Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.

A. Rosenwald, J. Powell, Liming Yang, 2006, Cancer research.

The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis.

W. Linehan, S. Hayward, T. Ried, 2001, Cancer research.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

D. Pfister, M. Schlumberger, J. Moley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells

R. Klausner, W. Linehan, J. Gnarra, 1999, Molecular and Cellular Biology.

Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location

P. Albert, P. Choyke, R. Klausner, 2004, Human mutation.

The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine

W. Linehan, N. Sopko, A. Mendoza, 2004, Clinical Cancer Research.

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

W. Linehan, M. Walther, S. Rosenberg, 2001, The Journal of urology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA).

E. Baudin, M. Santoro, M. Schlumberger, 2010 .

Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.

J. Trepel, T. Burke, Min-Jung Lee, 2007, Cancer research.

Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression

W. Linehan, W. Linehan, J. Mcmahon, 2006, Journal of biomolecular screening.

A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

P. Moore, J. Wigginton, J. Strauss, 2018 .

988PDCLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH HEAD AND NECK CANCER.

N. Segal, A. Balmanoukian, M. Fury, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.

W. Linehan, D. Bottaro, J. Vasselli, 2008, European urology.

A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer

L. Paz-Ares, R. Haddad, B. Robinson, 2008 .

Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.

A. Tolcher, P. Moore, J. Wigginton, 2016 .

A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

J. Maris, P. Moore, J. Wigginton, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.

R. Herbst, P. Elvin, A. Platt, 2013 .

A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer

P. Moore, J. Wigginton, R. Cohen, 2015, Journal of Immunotherapy for Cancer.

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer

P. Moore, N. Rizvi, J. Wigginton, 2015, Journal of Immunotherapy for Cancer.